Stockscreener 앱 받기
0.1222
19.87%
-0.0303
시간 외 거래:
.12
-0.0022
-1.80%
전일 마감가:
$0.1525
열려 있는:
$0.1571
하루 거래량:
29.98M
Relative Volume:
3.60
시가총액:
$8.03M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-38.41%
1개월 성능:
-37.08%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.1181
$0.1576
1주일 범위
$0.1181
$0.2013
52주 변동 폭
$0.1159
$2.22
Profusa Inc Stock (PFSA) Company Profile
명칭
Profusa Inc
전화
212-494-9022
주소
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
PFSA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.1222 | 10.02M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Profusa Inc 주식(PFSA)의 최신 뉴스
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study By Investing.com - Investing.com Australia
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - The Manila Times
Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - marketscreener.com
Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025 - TradingView — Track All Markets
Profusa (Nasdaq: PFSA) U.S. Lumee PAD study hits endpoints, backs potential FDA filing - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Profusa (Nasdaq: PFSA) to share US pilot PAD Lumee data at LINC 2026 in Leipzig - Stock Titan
The growth track for Profusa Inc (PFSA) has changed recently - setenews.com
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
Q&A: Real-time digital healthcare for 2026 - Digital Journal
Top investors say TSS Inc (TSSI) ticks everything they need - Setenews
How does Profusa Inc (PFSA) change from a tortoise to a hare? - Setenews
Profusa to Present Late Breaking U.S. Based Clinical Trial Update at Paris Vascular Insights 2025 - marketscreener.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 - The Manila Times
Profusa (PFSA) Competitors and Alternatives 2025 - MarketBeat
Profusa (PFSA) Stock Forecast and Price Target 2025 - MarketBeat
Profusa, Inc.Common Stock (NQ: PFSA - Markets Financial Content
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Profusa, Inc. (PFSA) -10.7% in Normal Trading: Decline Amid Recent Financial Update - Stocks Telegraph
Profusa raises USD 12M in gross proceeds from convertible PIPE note - Medical Buyer
Profusa Announces Q3 Highlights and Strategic Merger - TipRanks
Profusa, Inc. Announces Third Quarter 2025 Financial Results and Business Highlights - TradingView
Profusa (PFSA) 10K Form and SEC Filings 2025 - MarketBeat
Profusa Announces Third Quarter Business and Financial Highlights - The Manila Times
Profusa, Inc. SEC 10-Q Report - TradingView
[10-Q] Profusa, Inc. Quarterly Earnings Report | PFSA SEC FilingForm 10-Q - Stock Titan
Profusa, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
PFSA News Today | Why did Profusa stock go up today? - MarketBeat
Profusa (PFSA) Stock Price, News & Analysis - MarketBeat
Is Profusa Inc (PFSA) positioned for future growth? - Setenews
Profusa Delays Filing of Quarterly Report - MSN
[NT 10-Q] Profusa, Inc. SEC Filing - Stock Titan
[SCHEDULE 13G/A] Profusa, Inc. SEC Filing - Stock Titan
What is Profusa Inc (PFSA) Stock Return on Shareholders’ Capital? - Setenews
Profusa invests additional $1 million in digital treasury assets - MSN
Profusa, Inc. (PFSA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Profusa Inc (PFSA) looking to reclaim success with recent performance - setenews.com
Profusa, Inc. (PFSA) stock price, news, quote and history - Yahoo! Finance UK
[8-K] Profusa, Inc. Reports Material Event | PFSA SEC FilingForm 8-K - Stock Titan
Profusa outlines EU launch of tissue oxygen monitoring in 2026 - Investing.com India
Profusa outlines revenue plan, targets EU commercial launch of Lumee in early Q2 2026 - MSN
Profusa outlines EU launch of tissue oxygen monitoring in 2026 By Investing.com - Investing.com South Africa
Profusa Unveils Strategic Plan for Revenue Growth - TipRanks
Profusa, Inc. Outlines Path to $250 Million Revenue by 2030 - TradingView
Profusa Outlines Potential Path to $250 Million Revenue by 2030, Driven by Sequential Lumee™ Oxygen and Glucose Monitoring Launches - The Manila Times
Profusa Outlines Potential Path to $250 Million Revenue by - GlobeNewswire
Profusa (PFSA) Stock Skyrockets 36% on Milestone News – Can This Biotech Sensor Play Rebound? - ts2.tech
Why Profusa (PFSA) Stock Soared 36% After Hours? - Benzinga
[424B3] Profusa, Inc. Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
Profusa Inc (PFSA) 재무 분석
Profusa Inc (PFSA)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.42%
0.91%
자본화:
|
볼륨(24시간):